Errol B. Desouza - 30 Nov 2023 Form 4 Insider Report for Cyclerion Therapeutics, Inc. (CYCN)

Reporting relationship: Director
Issuer ticker: CYCN
Reported as of: 30 Nov 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Dec 2023, 16:05:07 UTC
Prior SEC filing: 26 Jun 2023
Next SEC filing: 21 Mar 2024
Source filing: View source filing
Reporting owner signature: /s/ ERROL B DESOUZA

Key filing fact

Errol B. Desouza filed Form 4 for Cyclerion Therapeutics, Inc. (CYCN) on 04 Dec 2023.

Key facts

This page summarizes Errol B. Desouza's Form 4 filing for Cyclerion Therapeutics, Inc. (CYCN).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 04 Dec 2023, 16:05.

Change

Previous filing in this sequence was filed on 26 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CYCN transaction

Common Stock

Award

Transaction value: $0
Shares: +20,000
Change %: +67%
Price: $0.000000
Shares after: 50,000
Date: 30 Nov 2023
Ownership: Direct
Footnotes: F1

CYCN transaction

Common Stock

Award

Transaction value: $0
Shares: +30,000
Change %
Price: $0.000000
Shares after: 30,000
Date: 30 Nov 2023
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Reporting Person was granted 20,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 2,500 of these shares vest immediately and the remaining 17,500 shares vest ratably over a 42-month period, provided that the Reporting Person remains as a director of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.

Footnote F2

The Reporting Person was granted 30,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 3,750 of these shares vest immediately and the remaining 26,250 shares vest ratably over a 42-month period, provided that the Reporting Person remains as Chair of the Board of Directors of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.